Meridian Life Science® Successfully Manufactures Flu Challenge Stock

HispanicBusiness.com reports that Meridian Life Science Inc. has manufactured an H1N1 influenza A challenge stock for Immune Targeting Systems, Ltd. A challenge stock is an infectious viral stock capable of inducing disease.

As quoted in the market news:

“Meridian has done a good job in generating a significant clinical stock of cGMP H1N1 influenza A. Manufacture of this virus allows us to move to the next phase of clinical development of our lead vaccine program,” said Dr. Campbell Bunce, R&D Director of Immune Targeting Systems. 

Click here for the full press release published on HispanicBusiness.com.